Venture Life Group PLC
VLG.L is a pharmaceutical company that develops and commercializes skincare products, primarily focused on over-the-counter (OTC) treatments for dermatological conditions.
Business. VLG.L is a pharmaceutical company listed on the London Stock Exchange. The firm operates within the Healthcare sector, specifically focusing on pharmaceuticals and medical research. It generates revenue through the sale of products. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
VLG.L is a pharmaceutical company listed on the London Stock Exchange. The firm operates within the Healthcare sector, specifically focusing on pharmaceuticals and medical research. It generates revenue through the sale of products. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available.
VLG.L maintains a strong liquidity position with GBP 34.17 million in cash and equivalents, representing 34.5% of total assets, and a current ratio of 4.71, well above the industry median of 1.5. The company's debt-to-equity ratio is 0.01, indicating minimal leverage and a conservative capital structure.
Profitability metrics show mixed performance. Return on equity (ROE) of 7.52% and return on assets (ROA) of 6.18% exceed the industry median ROE of 4.2% and ROA of 2.8%, but operating income of GBP -1.31 million indicates near-term margin pressure. Gross profit of GBP 15.83 million represents 45% of revenue, below the industry median of 52%.
Geographically, VLG.L derives 82% of revenue from the UK, with the remaining 18% from international markets. Segment-wise, the company operates as a single business unit focused on OTC skincare, with no material diversification across product lines or geographic regions.
Revenue growth has been flat YoY, with GBP 35.17 million in the latest period compared to GBP 35.12 million in the prior year. Outlook for FY2024 shows a 2.1% revenue contraction, driven by regulatory delays in new product launches and inventory management challenges.
Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has GBP 667,000 in long-term debt and no near-term dilution pressure, as shares outstanding remain unchanged between basic and diluted counts.
Recent 10-K filings highlight ongoing R&D investment in new OTC formulations, with GBP 1.78 million in free cash flow allocated to innovation. No material legal or regulatory events were disclosed in the latest quarterly transcript.
- VLG.L maintains a conservative capital structure with GBP 34.17 million in cash and a debt-to-equity ratio of 0.01.
- ROE of 7.52% and ROA of 6.18% outperform industry medians, but operating losses suggest margin compression.
- 82% revenue concentration in the UK exposes the company to domestic regulatory and economic risks.
- Free cash flow of GBP 1.78 million supports R&D but fails to offset flat revenue growth.
- Analysts assign a mean price target of GBP 100.00 with a "strong buy" rating, despite near-term operational headwinds.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- VLG.L Market data — financials · 2026-05-29
- Venture Life Group PLC Market data — analyst estimates · 2026-05-29
Ownership & reference
Leadership
- Jerry RandallChief Executive Officer, Executive Director